Specifically, the CardioGenomic Plus™ Profile evaluates genetic variations, called single nucleotide polymorphisms (SNPs) in genes that modulate blood pressure regulation, lipid balance, nutrient metabolism, inflammation, and oxidative stress.
This test uncovers potential genetic susceptibility to:
- Myocardial infarction
- Endothelial dysfunction
Specialized genomic testing from Genova Diagnostics can provide a glimpse into ones potential health future. Genetic testing enables one to minimize the risk by:
- Identifying hidden gene mutations that may promote chronic disease
- Preventing disease through early intervention
- Modifying gene expression through more precise, targeted, individualized interventions
- Identifying key areas for follow-up testing
- Monitoring therapeutic effectiveness of intervention strategies with laboratory testing
Whether or not you choose to see genes, they are always there and will continue to play an important role in one's health. With genomic testing, by choosing to look at them, you have the opportunity to influence the ultimate outcome and more actively promote a healthy life. The CardioGenomic Plus™ Profile evaluations include:
Cholesterol Regulation and Atherosclerosis
- ApoE (apolipoprotein E)
- CETP (cholesteryl ester transfer protein)
- SELE (selectin E)
These genes affect how the body breaks down and clears fats and how cholesterol is processed. They also affect lipid balance, plaque formation, and blood vessel integrity and function.
- MTHFR (methylenetetrahydrofolate reductase)
Polymorphisms of this enzyme can disrupt the metabolism of homocysteine, resulting in its accumulation as well as impaired methylation. The presence of these SNPs can increase risk of cardiovascular disease, blood vessel damage, thrombosis (blood clots), stroke, and degenerative aging.
- GNB3 (guanine nucleotide-binding protein)
- AGTR1 (angiotensin II receptor-1)
Polymorphisms of these genes are associated with blood vessel constriction, sodium and water retention, obesity, and increased susceptibility to hypertension.
- Factor 2 (prothrombin)
- Factor 5 (Leiden)
- PAI-1 (Plasminogen activator inhibitor-1)
- GP3a (Glycoprotein 3)
These genetic variants can over-activate blood clotting processes, increasing the risk of sudden cardiac events such as thrombosis, heart attacks, and strokes.